<DOC>
	<DOCNO>NCT01873443</DOCNO>
	<brief_summary>This open-label , single-arm , multicenter , efficacy , safety maintenance study Phase 1 Study CT-P10 1.1 . This study design assess long-term efficacy safety CT-P10 co-administered MTX folic acid patient RA complete schedule visit Study CT-P10 1.1</brief_summary>
	<brief_title>Long-Term Efficacy Safety CT-P10 Patients With RA</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<criteria>Patient disease improvement ( moderate good response ) accord Disease Activity Score use 28 joint count ( DAS28 ) last course treatment Study CTP10 1.1 . Patient complete schedule visit Study CTP10 1.1 Main Study Period , include Core Study Period and/or Extension Study Period . Patient withdrawn Study CTP10 1.1 reason . Patient , time provide informed consent , current medical issue serious adverse event ( SAEs ) current previous intolerance issue mean continuation maintenance study could detrimental health , opinion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>